Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses

Br J Dermatol. 2007 May:156 Suppl 3:57-61. doi: 10.1111/j.1365-2133.2007.07858.x.

Abstract

Diclofenac 3% gel is an effective treatment for actinic keratoses (AKs) and is reported to be generally well tolerated with only mild local reactions. However, there is a subset of patients that seem to be susceptible to developing severe local reactions following application of diclofenac 3% gel. Although some of these reactions can be explained as being allergic contact dermatitis and/or photoallergic contact dermatitis, others cannot. We report a series of 10 patients who all developed severe local reactions following application of diclofenac 3% gel, despite negative diclofenac patch testing. This raises the question as to whether there is a subset of patients with skin cancer or AK lesions that are highly/more susceptible to local reactions caused by cyclo-oxygenase-2 (COX-2) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists? We speculate that underlying molecular differences exist in these patients that make the skin more susceptible to COX-2 inhibitors.

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Cyclooxygenase 2 Inhibitors / administration & dosage
  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Diclofenac / administration & dosage
  • Diclofenac / adverse effects*
  • Diclofenac / pharmacology
  • Drug Eruptions / genetics*
  • Female
  • Gels
  • Humans
  • Keratosis / drug therapy*
  • Keratosis / genetics
  • Male
  • Middle Aged
  • Peroxisome Proliferator-Activated Receptors / genetics*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Gels
  • Peroxisome Proliferator-Activated Receptors
  • Diclofenac